<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239703</url>
  </required_header>
  <id_info>
    <org_study_id>ATAGC05</org_study_id>
    <nct_id>NCT04239703</nct_id>
  </id_info>
  <brief_title>INTERCOMEX Donor-Derived Cell Free DNA Study</brief_title>
  <official_title>INTERCOMEX DD-cfDNA-HLA-MMDx Study: Comparing the DD-cfDNA Test to MMDx Microarray Test, Central HLA Antibody Test, and Histology.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Natera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>One Lambda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the
      Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a need for better screening of kidney transplant patients for rejection. Patients
      with kidney transplants are routinely tested (creatinine, urine protein, histology and donor
      specific antibody (DSA) as standard of care to detect rejection, but these tests are not
      adequate. Rejection is often missed by these tests (false negatives) and other processes such
      as acute kidney injury can produce false-positive results. Moreover, histology has a high
      interobserver disagreement diagnosing rejection, and cannot accurately assess acute injury. A
      definitive molecular assessment of rejection and injury in kidney biopsies has emerged - the
      Molecular Microscope® Diagnostic System (MMDx) - developed by the Alberta Transplant Applied
      Genomics Centre, University of Alberta. Now a new screening test is being introduced: the
      monitoring of donor-derived cell-free DNA (DD-cfDNA) released in the blood by the kidney
      during rejection. The Natera Inc DD-cfDNA Prospera® test is based on the massively multiplex
      PCR that targets 13,392 single nucleotide polymorphisms and targeted sequences are quantified
      by Next Generation Sequencing. The Prospera® test done on kidney transplant recipients
      detected &quot;active rejection&quot; and differentiated it from borderline rejection and no rejection.
      It is likely, however, that DD-cfDNA test may miss some T cell-mediated rejection (TCMR)
      cases and the distinction between early and fully developed antibody-mediated rejection
      (ABMR) was not tested. No study has actually examined the DD-cfDNA results in kidney
      transplants with acute or chronic kidney disease (AKI and CKD). DD-cfDNA measurements have
      only been correlated with histology, a flawed standard. DD-cf-DNA test must now be calibrated
      against MMDx that is based on global gene expression, the new standard for biopsy
      interpretation. The present study will calibrate centrally measured (Natera Inc) DD-cfDNA
      levels obtained at the time of an indication biopsy against the MMDx measurements of TCMR,
      and ABMR (early-stage, fully-developed, and late-stage), AK, and atrophy-fibrosis. We will
      compare blood DD-cfDNA measurements in 600 samples at the time of 300 indication biopsies to
      the MMDx results, as well as central assessment of HLA antibody (One Lambda) in 300 blood
      samples, interpreted as DSA by the center based on the tissue typing results. This study is
      an extension of the INTERCOMEX ClinicalTrials.gov Identifier: NCT01299168
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calibration of Prospera test for T cell-mediated rejection</measure>
    <time_frame>18 months</time_frame>
    <description>Calibration of DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calibration of Prospera test for antibody-mediated rejection</measure>
    <time_frame>18 months</time_frame>
    <description>Calibration of DD-cfDNA test cut-off values against the probability of antibody-mediated rejection in the biopsy as reported by MMDx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calibration of Prospera test for kidney injury</measure>
    <time_frame>18 months</time_frame>
    <description>Calibration of DD-cfDNA test cut-off values against the probability of acute and chronic kidney injury in the biopsy as reported by MMDx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Report calibrated Prospera test results for rejection</measure>
    <time_frame>6 months</time_frame>
    <description>Report new DD-cfDNA test cut-off values for rejection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Report calibrated Prospera test results for kidney injury</measure>
    <time_frame>6 month</time_frame>
    <description>Report new DD-cfDNA test cut-off values for acute and chronic kidney injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine if Prospera blood test can replace kidney biopsy test</measure>
    <time_frame>6 months</time_frame>
    <description>Determine if Prospera test, as calibrated by this DD-cfDNA-HLA-MMDx study, will avoid need for indication biopsy when kidney transplant function deteriorates. This will be based on the consensus between participating clinicians.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of donor-specific antibody status</measure>
    <time_frame>6 months</time_frame>
    <description>Report and compare the DSA status based on centralized and local HLA antibody measurement.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Kidney transplant biopsies for cause</arm_group_label>
    <description>The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MMDx</intervention_name>
    <description>Portion of kidney transplant indication biopsy</description>
    <arm_group_label>Kidney transplant biopsies for cause</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Prospera</intervention_name>
    <description>Transplant patient blood sample</description>
    <arm_group_label>Kidney transplant biopsies for cause</arm_group_label>
    <other_name>transplant patient blood sample</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HLA antibody</intervention_name>
    <description>Transplant patient blood sample</description>
    <arm_group_label>Kidney transplant biopsies for cause</arm_group_label>
    <other_name>transplant patient blood sample</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA isolated from kidney biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients with a functioning kidney transplant undergoing a
        biopsy for clinical indications as standard of care to determine the cause of their graft
        dysfunction (deterioration in graft function, delayed graft function, proteinuria).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All kidney transplant recipients undergoing a kidney biopsy for clinical indications,
             as determined by their physician or surgeon, will be eligible to enroll in the study.

        Exclusion Criteria:

          -  Patients will be excluded from the study if they decline participation or are unable
             to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip F Halloran, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad S Famulski, PhD</last_name>
    <phone>1 780 492 1725</phone>
    <email>konrad@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Polakowski, PhD</last_name>
    <phone>1 780 492 5091</phone>
    <email>polakows@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital, Washington University at St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Malone</last_name>
      <email>amalone@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Malone, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta, Department of Medicine</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soroush Shojai, MD</last_name>
      <email>shojai@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Soroush Shojai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sita Gourishankar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Merkur Renal Division</name>
      <address>
        <city>Zagreb</city>
        <zip>1910000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeljka Jurekovic, MD</last_name>
      <email>zeljka.jurekovic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mladen Knotek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeljka Jurekovic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ksenija Vucur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>140 21 Praha 4</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Hruba, MD</last_name>
      <email>hrup@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Ondrej Viklicky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Hruba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvie Rajnochová Bloudíčkova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite-Medical University of Berlin Department of Nephrology</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Klemens Budde, MD</last_name>
      <email>klemens.budde@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Monique Greiner-Pol</last_name>
      <email>monique.greiner-pol@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Klemens Budde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre of Nephrology, Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marius Miglinas</last_name>
      <email>marius.miglinas@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Marius Miglinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology and Transplantation Medical University in Bialystok</name>
      <address>
        <city>Białystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital nr1 Bydgoszcz, Klinika Transplantologii</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew Włodarczyk, MD</last_name>
      <email>wlodarczyk@cm.umk.pl</email>
    </contact>
    <investigator>
      <last_name>Zbigniew Włodarczyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdańsk Klinika Nefrologii Transplantologii i Chorób Wewnętrznych</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-259</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Chamienia, MD</last_name>
      <email>chamien@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Alicja Dębska-Ślizień, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Konopa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrzej Chamienia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <zip>40-027</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grzegorz Piecha, MD</last_name>
      <email>g.piecha@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Grzegorz Piecha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Transplantation and General Surgery, Wojewodzki Hospital</name>
      <address>
        <city>Poznań</city>
        <zip>60-479</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Glyda, MD</last_name>
      <email>glydam@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Maciej Glyda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Smykal-Jankowiak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Transplantation and Internal Medicine, University Hospital n.2</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leszek Domański, MD</last_name>
      <email>domanle@pum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Leszek Domański, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pomeranian Medical University, Samodzielny Publiczny Woj. Szpital Zespolony, Oddzial Nefrologii i Transplantacji Nerek</name>
      <address>
        <city>Szczecin</city>
        <zip>71-455</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Myślak, MD Phd</last_name>
      <email>marek.myslak@pum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Myślak, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Mazurkiewicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Gryczman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw, Department of Transplantation Medicine, Nephrology and Internal Diseases</name>
      <address>
        <city>Warsaw</city>
        <zip>02-006</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Durlik, MD</last_name>
      <email>magdalena.durlik@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Magdalena Durlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Transplant Medicine &amp; Nephrology Clinic, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-006</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Perkowska-Ptasińska, MD PhD</last_name>
      <email>aggape@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Agnieszka Perkowska-Ptasińska, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominika Dęborska-Materkowska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michał Ciszek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Memorial Health Institute, Department of Nephrology, Kidney Transplantation and Hypertension</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryszard Grenda, MD</last_name>
      <email>r.grenda@ipczd.pl</email>
    </contact>
    <investigator>
      <last_name>Ryszard Grenda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University, Department of Nephrology and Transplantation Medicine</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirosław Banasik, MD</last_name>
      <email>m.banasik@interia.pl</email>
    </contact>
    <investigator>
      <last_name>Mirosław Banasik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, University Medical Centre</name>
      <address>
        <city>Ljubljana</city>
        <zip>21000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nika Kojc, MD</last_name>
      <email>nika.kojc@mf.uni-lj.si</email>
    </contact>
    <investigator>
      <last_name>Miha Arnol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nika Kojc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Muller, MD PhD</last_name>
      <email>Thomas.Mueller@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Muller, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Philip Halloran</investigator_full_name>
    <investigator_title>Distinguished Professor</investigator_title>
  </responsible_party>
  <keyword>donor derived cell-free DNA</keyword>
  <keyword>blood</keyword>
  <keyword>kidney biopsy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

